Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05965258
Other study ID # 23-702
Secondary ID 1R01HL170090-01
Status Recruiting
Phase
First received
Last updated
Start date August 29, 2023
Est. completion date December 31, 2028

Study information

Verified date October 2023
Source The Cleveland Clinic
Contact Deborah Kwon, MD
Phone 216-444-8526
Email kwond@ccf.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of the current research is to develop personalized risk prediction for functional mitral regurgitation (FMR) patients through explainable unsupervised phenomapping enriched with advanced cardiac magnetic resonance (CMR) imaging biomarkers, and to determine the CMR predictors of reverse remodeling following modern therapies for FMR. The prospective study entails aiming to recruit 360 adult patients (ages >18 years) with EF 10-50% and FMR RF> 20%, who are clinically referred for CMR evaluation. Patients who enroll in our study will be referred for optimization of mGDMT and will undergo follow-up CMR studies at 6months. NICM patients who are fully medically optimized with significant FMR at the time of the baseline CMR and are referred for Mitraclip treatment will undergo follow-up CMR 6 months from Mitraclip intervention. NICM patients referred for mGDMT optimization, but have persistent or progressive FMR at the time of 6 month follow-up CMR and referred for Mitraclip therapy, will undergo a 2nd follow-up CMR 6 months from Mitraclip therapy.


Description:

Functional mitral regurgitation (FMR) portends a bleak prognosis and is a common consequence of ischemic and non-ischemic cardiomyopathy (ICM, NICM), where adverse annular and left ventricular (LV) remodeling and/or infarction alters mitral valve (MV) function. Prior studies demonstrate significant increases in mortality risk as severity of FMR increases; mortality rates range from 15-40% at 1 year. Furthermore, as the prevalence of heart failure (HF) is rising, FMR is projected to double from over 2 million patients in 2000 to over 4 million patients in the United States by 2030. Defining FMR severity, optimal timing of intervention, and most appropriate method for intervention remain controversial. Recently, MITRA-FR and COAPT trials demonstrated contrasting survival benefit with percutaneous MV repair, demonstrating the importance and need for more optimal selection criteria. Currently, the patient selection criteria for Mitraclip therapy are solely based on MV anatomy and controversial echocardiographic criteria for FMR severity. Cardiac magnetic resonance (CMR) provides an exciting opportunity to address numerous unmet needs regarding characterizing FMR and the need for more optimal selection criteria for improving outcomes. Superior accuracy and reproducibility for quantification of LV size and function, and gold standard tissue characterization, positions CMR as the ideal imaging modality for comprehensively characterizing FMR and the underlying myopathic processes that significantly impact response to FMR therapies. The goal of the current research is to develop personalized risk prediction for FMR patients through explainable unsupervised phenomapping enriched with advanced CMR imaging biomarkers, and to determine the CMR predictors of reverse remodeling following modern therapies for FMR. The proposed research will leverage a large retrospective single center NICM CMR database. Our CMR NICM database currently features 458 NICM patients, who underwent CMR on a single CMR vendor platform from 2008-2017, who have been extensively curated with contoured data for standard CMR measures. An additional 802 NICM patients have been identified from our 2018-2021 CMR database with EF<50% with the same inclusion/exclusion criteria, which will be extensively curated to enable phenomapping discovery. An external 400 NICM patient cohort will be used as an external validation cohort. The prospective study entails aiming to recruit 360 adult patients (ages >18 years) with EF 10-50% and FMR RF> 20%, who are clinically referred for CMR evaluation. Patients who enroll in our study will be referred for optimization of mGDMT with Heart Failure Pharmacist Clinic and followed every 2 weeks until optimized. All will return and undergo follow-up CMR studies at 6months. NICM patients who are fully medically optimized with significant FMR at the time of the baseline CMR and are referred for Mitraclip treatment will undergo follow-up CMR 6 months from Mitraclip intervention. NICM patients referred for mGDMT optimization, but have persistent or progressive FMR at the time of 6 month follow-up CMR and referred for Mitraclip therapy, will undergo a 2nd follow-up CMR 6 months from Mitraclip therapy. CMR will be done on dedicated cardiac research MRI scanner.


Recruitment information / eligibility

Status Recruiting
Enrollment 360
Est. completion date December 31, 2028
Est. primary completion date December 31, 2028
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1 CMR LVEF <50% 2.FMR Fraction>20%, with adequate image quality and no evidence of severe obstructive CAD Exclusion Criteria: 1. >moderate aortic regurgitation/stenosis, 2. <18 years of age, 3. acute myocarditis, 4. eGFR<15 5. HCM 6. cardiac amyloidosis/sarcoidosis 7. prior mitral valve intervention 8. myocardial infarction within 8 weeks of CMR 9. ischemic infarct pattern on CMR

Study Design


Intervention

Diagnostic Test:
Cardiac magnetic resonance (CMR)
Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio

Sponsors (2)

Lead Sponsor Collaborator
The Cleveland Clinic National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite of cardiac mortality, heart transplant, or LVAD implantation. Occurrence of cardiac mortality and/or heart transplant and/or LVAD implantation Up to 36 months
Secondary Change in FMR a change of >5 units/percentage points compared to baseline 6 months
Secondary Change in NT-proBNP 30% change in NT-proBNP or decrease to level < 1000 compared to baseline 6 months
Secondary Change in KCQL score 5 point change in KCQL score compared to baseline 6 months
Secondary Change in 6-minute walk test 25 meter change in 6-minute walk test compared to baseline 6 months
Secondary Recurrent heart failure hospitalization Occurrence of heart failure related hospitalization up to 1 year
Secondary Arrhythmias Occurrence of arrhythmia up to 1 year
Secondary MI Occurrence of myocardial infarction up to 1 year
Secondary Stroke Occurrence of stroke up to 1 year
Secondary Heart transplant Occurrence of heart transplant up to 1 year
Secondary LVAD implantation Occurrence of implant of left ventricular assisted device (LVAD) up to 1 year
Secondary Mortality Occurrence of mortality up to 1 year
See also
  Status Clinical Trial Phase
Completed NCT02520310 - AVJ-514 Japan Trial N/A
Not yet recruiting NCT04396379 - Epicardial Mitral Touch System for Mitral Insufficiency N/A
Not yet recruiting NCT05566340 - Treatment of Moderate FMR During AVR
Completed NCT01899573 - Percutaneous Left Ventricular Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function N/A
Terminated NCT04529928 - An Initial Evaluation of the Carillon Mitral Contour System for Treatment of Atrial Function Mitral Regurgitation N/A
Recruiting NCT03706833 - Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial N/A
Completed NCT00800046 - A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study N/A
Active, not recruiting NCT03929913 - NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study N/A
Active, not recruiting NCT05988450 - Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation N/A
Recruiting NCT03616678 - VenTouch OUS Feasibility Study N/A
Not yet recruiting NCT04679714 - EXPLORE FMR: Early Feasibility Study of the PLAR Implant and Delivery System to Treat Functional Mitral Regurgitation N/A
Active, not recruiting NCT02701972 - Evaluation of Safety and Efficacy of the BACE™ Device in the Treatment of Functional Mitral Valve Regurgitation [FMR N/A
Enrolling by invitation NCT04776798 - Biomechanical Taping on Low Back Pain With Increased Foot Pronation N/A
Enrolling by invitation NCT05677568 - The CINCH-FMR Post-Market Registry: Percutaneous Repair in Functional Mitral Regurgitation
Recruiting NCT03433274 - Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation N/A
Completed NCT05865938 - PASCAL vs. MitralClip for Mitral Valve Transchatheter Edge-to-Edge Repair
Terminated NCT03016975 - Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE) N/A
Completed NCT02471664 - Mitral Loop Cerclage(MLC) for Reducing Functional Mitral Regurgitation N/A
Active, not recruiting NCT02671799 - Evaluation of the Minimally Invasive VenTouch™ System in the Treatment of Functional Mitral Valve Regurgitation (FMR) N/A
Recruiting NCT03142152 - The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR N/A